Related references
Note: Only part of the references are listed.Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]
Tadakazu Hisamatsu et al.
JOURNAL OF CROHNS & COLITIS (2019)
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
Laura E. Targownik et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy
Alessandro Sartini et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience
Lieven Pouillon et al.
INFLAMMATORY BOWEL DISEASES (2019)
Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease
Kenji Watanabe et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Combination Immunosuppression in IBD
Steven Bots et al.
INFLAMMATORY BOWEL DISEASES (2018)
Evidence-based clinical practice guidelines for inflammatory bowel disease
Katsuyoshi Matsuoka et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
J-F. Colombel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis
Laura E. Targownik et al.
INFLAMMATORY BOWEL DISEASES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial
H. Nakase et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab
Kaoru Yokoyama et al.
ADVANCES IN THERAPY (2016)
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial
Takayuki Matsumoto et al.
JOURNAL OF CROHNS & COLITIS (2016)
Effectiveness and Safety of lmmunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
Mark T. Osterman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials
Jennifer L. Jones et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Treatment of ulcerative colitis
Wojciech Blonski et al.
CURRENT OPINION IN GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prevalence of ulcerative colitis and Crohn's disease in Japan
Keiko Asakura et al.
JOURNAL OF GASTROENTEROLOGY (2009)
Share Paper
